Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Drug trail failure sends Cytokinetics plunging

 (Image source: pharmafile.com)

Shares of the biopharmaceutical company Cytokinetics, Inc. (NASDAQ:CYTK) are in a freefall after its drug Tirasemtiv failed to reach its primary goal in the treatment of Lou Gehrig’s disease. The drug failed to yield improvement in muscle function. Shares are currently down an astonishing 60 percent.